Plasma Level Of miR-21 And miR-451 In Primary And Recurrent Breast Cancer Patients

Figures & data

Table 1 Clinicopathological Characteristics Of BC Patients

Clinicopathologic Features	Primary BC	Recurrent BC	P-Value
Grade			0.342
I	8	3
II	4	6
III	4	3
Stage			0.001
I	6	0
II	17	7
III	0	4
IV	0	3
ER			0.621
Positive	5	13
Negative	2	3
PR			1.000
Positive	5	11
Negative	2	5
Her2			0.621
Positive	2	3
Negative	5	13
Node metastasis			0.017
Positive	9	16
Negative	10	8
Histopathology			–
ILC	1	2
IDC	14	15
DCIS	7	1
IDC/DCIS	0	2
IDC/ILC	1	1
Site of recurrence			–
Breast	0	1
Bone	0	9
Liver	0	5
Lung	0	4
Time of recurrence (month)			–
0–12	0	5
12–36	0	4
36–60	0	9

Note: P-values are based on Fisher’s exact test.

Abbreviations: ER, estrogen receptor; PR, progesterone receptor; Her2, human epidermal growth factor receptor 2; ILC, invasive lobular carcinoma; IDC, invasive ductal carcinoma; DCIS, ductal carcinoma in situ.

Table 2 The Plasma Expression Level Of miR-21 And miR-451

Recurrent BC	Primary BC	Healthy Individuals
5.6 (2.16–12.47)	2.44 (1.55–4.305)	0.9 (0.672–1.977)	miR-21 median (quartiles)
<0.001^a	<0.001^a	-	P-value
0.481^b
2.53 (1.04–6.99)	2.64 (1.15–5.005)	1.32 (0.319–1.887)	miR-451 median (quartiles)
0.06^a	0.065^a	-	P-value
1^b

Notes: P-values are based on Kruskal–Wallis test followed by Dunn test. ^aBetween BC patients and healthy individuals. ^bBetween the two BC patient groups.

Figure 1 Relative expression level of miRNAs in plasma of BC patients and healthy women. The elevation of miR-21 is significant in both primary (non-recurrent) and recurrent patients compared with healthy women. The increased level of miR-451 is not significant in patients than in controls. The ratio between the interest miRNAs and the reference gene was calculated to determine relative expression levels.

Figure 2 Validation of miR-21 in BC patients and healthy controls. Graphs of receiver operating characteristics (ROC) curve show the area under the curves (AUCs) of miR-21 for discriminating the primary BC patients (A) and the recurrent BC patients (B) from the healthy controls. The interval confidence level was 95%.

Figure 3 Positive regulation of miR-21 in cancers: Different signaling pathways positively regulate miR-21 expression through the activation of several transcription factors or by post-transcriptional processing of miR-21.